Patents by Inventor Dave Nichols

Dave Nichols has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE ANTI-OSMR ANTIBODY FORMULATION
    Publication number: 20250114449
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: May 23, 2024
    Publication date: April 10, 2025
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • COMPOSITIONS COMPRISING IDURONATE-2-SULFATASE
    Publication number: 20240401010
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Application
    Filed: April 24, 2024
    Publication date: December 5, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Dave Nichols
  • METHODS FOR PURIFICATION OF ARYLSULFATASE A
    Publication number: 20240392268
    Abstract: The present invention provides, among other things, improved methods for purifying arylsulfatase A (ASA) protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant ASA protein can be purified from unprocessed biological materials, such as, ASA-containing cell culture medium, using a process involving as few as four chromatography columns and only one step of post-chromatographic ultrafiltration/diafiltration.
    Type: Application
    Filed: December 22, 2023
    Publication date: November 28, 2024
    Inventors: Dave Nichols, Igor Quinones-Garcia, Bee Lin Cheang, Mei Huei Jang
  • COMPOSITIONS COMPRISING IDURONATE-2-SULFATASE
    Publication number: 20240043817
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Application
    Filed: November 3, 2022
    Publication date: February 8, 2024
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Dave Nichols
  • Methods for purification of arylsulfatase A
    Patent number: 11884945
    Abstract: The present invention provides, among other things, improved methods for purifying arylsulfatase A (ASA) protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant ASA protein can be purified from unprocessed biological materials, such as, ASA-containing cell culture medium, using a process involving as few as four chromatography columns and only one step of post-chromatographic ultrafiltration/diafiltration.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: January 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Dave Nichols, Igor Quinones-Garcia, Bee Lin Cheang, Mei Huei Jang
  • METHODS FOR PURIFICATION OF ARYLSULFATASE A
    Publication number: 20230235303
    Abstract: The present invention provides, among other things, improved methods for purifying arylsulfatase A (ASA) protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant ASA protein can be purified from unprocessed biological materials, such as, ASA-containing cell culture medium, using a process involving as few as four chromatography columns and only one step of post-chromatographic ultrafiltration/diafiltration.
    Type: Application
    Filed: July 1, 2022
    Publication date: July 27, 2023
    Inventors: Dave Nichols, Igor Quinones-Garcia, Bee Lin Cheang, Mei Huei Jang
  • Compositions comprising iduronate-2-sulfatase
    Patent number: 11530393
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: December 20, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: Dave Nichols
  • PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME
    Publication number: 20220281914
    Abstract: The instant invention relates to compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, e.g., an anti-GM-CSFR? antibody or antigen binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such compositions. Methods for using such compositions to treat a disorder, e.g., a GM-CSFR?-associated disorder, are also provided.
    Type: Application
    Filed: December 17, 2021
    Publication date: September 8, 2022
    Applicant: KINIKSA PHARMACEUTICALS, LTD.
    Inventors: Mei Jang, Dave Nichols, Baochuan Huang, Shaun Grier
  • Methods for purification of arysulfatase A
    Patent number: 11407984
    Abstract: The present invention provides, among other things, improved methods for purifying arylsulfatase A (ASA) protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant ASA protein can be purified from unprocessed biological materials, such as, ASA-containing cell culture medium, using a process involving as few as four chromatography columns and only one step of post-chromatographic ultrafiltration/diafiltration.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: August 9, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Dave Nichols, Igor Quinones-Garcia, Mei Huei Jang, Bee Lin Cheang
  • Stable Anti-OSMR Antibody Formulation
    Publication number: 20220062414
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: September 8, 2021
    Publication date: March 3, 2022
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • METHODS AND COMPOSITIONS FOR TREATMENT OF HUNTER SYNDROME
    Publication number: 20210317426
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Application
    Filed: November 6, 2020
    Publication date: October 14, 2021
    Inventor: Dave Nichols
  • Stable anti-OSMR antibody formulation
    Patent number: 11141479
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: October 12, 2021
    Assignee: KINIKSA PHARMACEUTICALS, LTD.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • Stable Anti-OSMR Antibody Formulation
    Publication number: 20200061188
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: August 26, 2019
    Publication date: February 27, 2020
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Philip M Levesque, Ryan Erik Holcomb
  • Stable anti-OSMR antibody formulation
    Patent number: 10493149
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: December 3, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • METHODS AND COMPOSITIONS FOR TREATMENT OF HUNTER SYNDROME
    Publication number: 20190359958
    Abstract: The present invention provides, among other things, improved methods for purifying 12S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant 12S protein can be purified from unprocessed biological materials, such as, 12S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Application
    Filed: May 20, 2019
    Publication date: November 28, 2019
    Inventor: Dave Nichols
  • Stable anti-OSMR antibody formulation
    Patent number: 10391170
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 27, 2019
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • Methods and compositions for treatment of Hunter syndrome
    Patent number: 10344270
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 9, 2019
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Dave Nichols
  • Migration velocity analysis using seismic data
    Patent number: 10288751
    Abstract: A technique includes receiving seismic data acquired by an array of seismic sensors during a towed marine survey of a subsurface and performing migration velocity analysis to determine a background velocity model of the subsurface based at least in part on particle motion derived from the seismic data.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: May 14, 2019
    Assignee: WESTERNGECO L.L.C.
    Inventors: Phil Kitchenside, Dave Nichols, Susanne Rentsch, Gabriele Busanello
  • STABLE ANTI-OSMR ANTIBODY FORMULATION
    Publication number: 20190054169
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: November 2, 2018
    Publication date: February 21, 2019
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M Levesque, Ryan Erik Holcomb
  • STABLE ANTI-OSMR ANTIBODY FORMULATION
    Publication number: 20180333489
    Abstract: The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
    Type: Application
    Filed: April 11, 2018
    Publication date: November 22, 2018
    Inventors: Mark Cornell Manning, Zahra Shahrokh, Dave Nichols, Phillip M. Levesque, Ryan Erik Holcomb